Cardiovascular-Kidney-Metabolic (CKM) syndrome describes interconnected conditions including type 2 diabetes (T2D), hypertension, hypertriglyceridemia, metabolic syndrome, and chronic kidney disease (CKD). As CKM advances, cardiorenal risk rises. Glucagon-like peptide-1 receptor agonists (GLP-1 RA) have demonstrated cardiorenal and cardiometabolic benefits and thus represent an opportunity to slow CKM progression. The authors aimed to evaluate whether social determinants of health (SDoH) influence access to GLP-1 RA among patients with T2D and other stage 2 CKM conditions using nationally representative data.
This was a cross-sectional study using data from the U.S. National Health and Nutrition Examination Survey (NHANES) covering survey cycles from 2005 through 2020. The analysis included adults aged 30 years or older with T2D and/or other stage 2 CKM conditions. The investigators applied survey weighting to generate nationally representative estimates and used weighted descriptive statistics, multivariable logistic regression, and LASSO (least absolute shrinkage and selection operator) for variable selection and association assessment.
The analytic sample comprised 4,520 NHANES participants, representing approximately 84.0 million U.S. adults. The weighted mean age was 61.4 years, 48.9% were female, and 61.5% were non-Hispanic White. These characteristics describe the population in whom GLP-1 RA prescribing patterns and SDoH associations were assessed.
The study examined multiple SDoH domains relevant to medication access and use. Reported variables included educational attainment, household income, health insurance coverage, marital status, and access to routine places for care. The authors used these variables to compare GLP-1 RA use across socioeconomic and access strata and to identify predictors of use via multivariable and LASSO approaches.
Reported subgroup comparisons indicated higher observed GLP-1 RA use among individuals with greater socioeconomic resources and health care access. Specifically, GLP-1 RA use was higher among participants with higher education (3.39% vs 1.43%), those with private insurance (3.00% vs 0.58%), and those in higher income categories (4.70% vs 1.87%). The study also reported that no GLP-1 RA use was observed among participants without routine places for care.
In adjusted logistic regression analyses reported in the source, several SDoH were associated with markedly lower likelihoods of GLP-1 RA use. Individuals with lower income, less than high school education, lack of insurance, and being unmarried had 64%, 51%, 81%, and 40% lower likelihoods of GLP-1 RA use, respectively. A LASSO model identified income, education, insurance status, and access to care as predictive variables for GLP-1 RA use.
An additional set of adjusted analyses controlling for age, sex, and race/ethnicity reported that lower income, lower educational attainment, and lack of insurance were associated with 48%, 34%, and 79% lower likelihoods of GLP-1 RA use, respectively. These findings were consistent across analytic approaches in the source document and emphasize socioeconomic and access-related barriers.
The study's findings indicate that SDoH-driven disparities are associated with reduced use of GLP-1 RA among adults with T2D and stage 2 CKM conditions. Because GLP-1 RA have reported cardiorenal and cardiometabolic benefits, limited access in socioeconomically disadvantaged groups may contribute to faster CKM progression and widening cardiovascular and kidney health disparities. The authors highlight that expanding access to GLP-1 RA by addressing socioeconomic barriers—such as insurance coverage, affordability, and access to routine care—could be important for slowing CKM progression and reducing population-level cardiorenal risk.
As reported in the source, the analysis is cross-sectional and based on NHANES observational data; causal inference is therefore limited. The study used publicly available, de-identified NHANES data and was considered exempt from institutional review board review. The source is a preprint and has not been peer reviewed; the authors and medRxiv note that the findings should not by themselves guide clinical practice. Specific limitations such as measurement details, residual confounding, or the potential for misclassification of medication use were not enumerated in the abstract and would require consultation of the full text for additional detail.
Using NHANES 2005–2020 data, the authors report that socioeconomic factors and health care access are strongly associated with the likelihood of GLP-1 RA use among adults with T2D and stage 2 CKM conditions. Lower income, lower educational attainment, lack of insurance, and limited access to routine care were linked to substantially reduced GLP-1 RA use. The source concludes that addressing SDoH and expanding access to GLP-1 RA is critical to slow CKM progression, reduce cardiovascular risk, and mitigate health disparities. Because this work is a preprint, the findings should be interpreted with caution pending peer review and further study.